Nucleic Acid Aptamers Market - Forecast(2024 - 2030)

Report Code: HCR 0985 Report Format: PDF + Excel

Nucleic Acid Aptamers Market

Nucleic Acid Aptamers Market Size is estimated to reach $481 million by 2028 and it is poised to grow at a CAGR of 17.3% over the forecast period of 2023-2028. Aptamers are small single-stranded oligonucleotides (DNAs or RNAs) with comparatively low molecular weight, ranging from 5-40 kDa. The following helps in forming a specific three-dimensional structure. Nucleic acid aptamer groups have more flexibility and minor complexity and immunogenicity allowing them to attach to interior non-accessible epitopes that cannot be easily targeted by antibodies. Aptamer sciences have been applied in various life sciences fields as a new drug, an agent for diagnostic and bio-imaging, drug-delivery agents, analytical reagents and food & hazard detection applications. The nucleic acid aptamers market in the U.S. has been majorly driven by the aptamer companies in the U.S. who are constantly evolving the sphere of research to curate products and services which serve a wider purpose. Owing to the following reasons, the industry will grow at a stupendous pace in the forecast period of 2023-2028.

Nucleic Acid Aptamers Market Report Coverage

The report: “Nucleic Acid Aptamers Market Forecast (2023-2028)" by IndustryARC, covers an in-depth analysis of the following segments in the Nucleic Acid Aptamers Market.

By Types – DNA Aptamers, XNA Aptamers and RNA Aptamers.
By Technology - SELEX and Others.
By Applications - Therapeutics Developments, Drug Delivery Agents, Analytical Reagents, Food Inspection and Hazard Detection, Diagnostic and Bio-Imaging Agent and Others.
By Geography: North America (the U.S., Canada and Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia and the Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia and New Zealand and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of the World (the Middle East and Africa).

Key Takeaways

  • Geographically, North America dominated the market in 2021. It is owing to the presence of robust healthcare infrastructure, supported by both public and private funding. However, Europe is expected to offer lucrative growth opportunities over the forecast period of 2023-2028. It is owing to tremendous development in the healthcare structure, with rising professional streams providing support.
  • The rising awareness of the advantages of aptamers over antibodies along with technological growth and support from the rising disease spectrum are the recognized drivers for the market. However, a shortage of skilled and trained professionals to handle a highly nuanced stream of research impedes the market.
  • A detailed analysis of the strengths, weaknesses, opportunities and threats will be provided in the Nucleic Acid Aptamers Market Report.

Nucleic Acid Aptamers Market- Market Share (%) by region, 2021.

Nucleic Acid Aptamers Market

For More Details on This Report - Request for Sample

Nucleic Acid Aptamers Market - by Technology

Nucleic Acid Aptamers Market by technology can be further segmented into SELEX and Others. The SELEX segment held a dominant market share in 2021 and is estimated to be the fastest-growing, with a CAGR of 18.7% over the forecast period of 2023-2028. SELEX is an acronym for systematic evolution of ligands by exponential enrichment. The main advantage of this procedure is to select aptamers, as nucleic acid-based affinity ligands, without any prior knowledge of the target. One of the modified SELEX procedures is the Cell-SELEX, which is used to discover specific aptamers against a whole cell. Furthermore, the oligonucleotide libraries are 40-100 bases long with 1012 to 1016 distinct sequences. Amplification can be facilitated by PCR and NGS. Lastly, the reduction in the price of sequencing a human genome to $942 in 2019 has facilitated the adoption.

Nucleic Acid Aptamers Market - by Application

Nucleic Acid Aptamers Market by the application can be further segmented into Therapeutics Developments, Drug Delivery Agents, Analytical Reagents, Food Inspection and Hazard Detection, Diagnostic and Bio-Imaging Agent and Others. Therapeutics Development held a dominant market share in the year 2021. The therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. For example, nucleic acid aptamers are used as an anti-biofilm agent for pneumonia, which as per WHO kills nearly 740,180 children in 2019. However, a diagnostic and bio-imaging agent is estimated to be the fastest-growing, with a CAGR of 17.8% over the forecast period of 2023-2028. It is owing to its aid in diagnosing the rising prevalence of chronic diseases across the globe.

Nucleic Acid Aptamers Market - by Geography

North America dominated the market in 2021 with a market share of 40%. It is owing to a stupendous medical infrastructure in America, which supersedes the nucleic acid aptamers market research. However, Europe is estimated to be the fastest-growing region over the forecast period of 2023-2028. It is owing to tremendous growth potential and revenue increment capacity in the region. Further, the nucleic acid aptamers market in the U.K. along with Germany will provide a much-needed growth impetus during the projected period. As per European Commission, EU-based companies increased investments in R&D in the health sector by 10.3% in 2021.

Nucleic Acid Aptamers Market Drivers

The Growing Role of Bacterial-Resistant Diseases Amongst Other Diseases Classes has Proliferated Market Growth.

Aptamers, other than recognized forms of therapeutic treatment, are highly regarded as antimicrobial agents. Further, biofilm-forming bacteria, which result in chronic infections, have developed increased resistance against antibiotic treatments and host defense systems, curating a demand for aptamers in therapeutic applications. Bacterial drug resistance has been on a significant rise, with approved antibacterial drugs with the new mechanism on a decline. As per CDC, in 2019 around 2.8 million anti-microbial resistance infections took place in the U.S., claiming nearly 35,000 lives. Owing to the presence of anti-biofilm activity, the technology is highly regarded in fatal infections.

Rising Awareness of the Advantages of Aptamers Over Antibodies has Prevailed to Increase Market Use.

Antibodies have presented a strong challenge for targeting small molecules, however, aptamers have conducted effectivity in targeting small molecules. Owing to this they can bind to small molecules and dyes and thus be easily used in conventional diagnostic kits, extending their use to point-of-care diagnostics. Furthermore, aptamers are successful to bind with larger molecules as well. Nearly 98% of all the molecules tend to be proteins, which intrinsically are larger than the rest. Hence, biomarkers and diagnostic kits utilize the concept of aptamers- thereby leveraging the growth of the nucleic acid aptamers industry.

Nucleic Acid Aptamers Market Challenges

A Critical Shortage of Skilled and Trained Professionals for the Application of Aptamers Impedes Market Growth.

Owing to the complexity, the development of aptamers is for various therapeutic and diagnostic purposes. These processes are highly technical and involve the use of various complex instruments and laboratory documentation systems. All these factors make aptamer development a tedious process and thus limit its uptake among researchers. Further, modified forms of SELEX are needed to apply. As per Forbes 2021, within U.S. and Canada, roughly one medical laboratory scientist is available per 1000 people, with higher burnout ratios reported in people owing to COVID-19. As per the American Society of Clinical Pathology, nearly 85.3% of lab professionals reported burnout while 36.5% complained of inadequate staffing.

Nucleic Acid Aptamers Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Nucleic Acid Aptamers Industry. The top 10 companies in the Nucleic Acid Aptamers market are:

  1. Aptamer Group
  2. Raptamer Discovery Group
  3. Soma-Logic
  4. Aptamer Sciences
  5. Aptagen
  6. Maravai Lifesciences
  7. Kaneka Corporation
  8. Neo Ventures Biotechnology
  9. Aptus Biochem
  10. Base Pair Technologies

Recent Developments

  • In September 2022, Cage Bio- A biotech company and TAGCyx Biotechnology Company announced the execution of a license-based agreement for the development of TAGX-0003. TAGX-0003 is a DNA aptamer possessing potent interferon-gamma (IFNg) antagonistic activity developed by TAGCyx. Under this agreement, CAGE Bio will receive an exclusive worldwide license to develop and commercialize the drug, excluding Japan.
  • In September 2022, Nutromics raised $14 million as Dexcom signaled to move into wider sensing capabilities. Nutromics is working on a portfolio of aptamer-based sensors capable of measuring a wide range of analytes.
  • In June 2022, Waseda University researchers developed RaptGen, a variational autoencoder that efficiently discovers new aptamers not included in the input SELEX dataset. This novel computational model could one day be the standard method for aptamer generation.

Relevant Titles

Enzyme Inhibitors Market- Industry Analysis, Market Size, Market Share, Trends, Application Analysis and Forecast Analysis.

Report Code- HCR 0289

Acetonitrile Market- Industry Analysis, Market Size, Market Share, Market Trends, Application Analysis and Forecast Analysis.

Report Code- CMR 0256

Antibodies Market- Industry Analysis, Market Size, Market Share, Trends, Application Analysis and Forecast Analysis

Report Code- HCR 22428

For more Lifesciences and Healthcare Market reports, please click here

1. Nucleic Acid Aptamers Market - Overview
    1.1 Definitions and Scope
2. Nucleic Acid Aptamers Market - Executive Summary
3. Nucleic Acid Aptamers Market - Comparative Analysis
    3.1 Company Benchmarking - Key Companies
    3.2 Global Financial Analysis - Key Companies
    3.3 Market Share Analysis - Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Nucleic Acid Aptamers Market - Start-up Companies Scenario Premium
    4.1 Key Start-up Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Nucleic Acid Aptamers Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Nucleic Acid Aptamers Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porter's Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Nucleic Acid Aptamers Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Nucleic Acid Aptamers Market – by Types
    8.1 DNA Aptamers
    8.2 XNA Aptamers
    8.3 RNA Aptamers
9. Nucleic Acid Aptamers Market – by Technology
    9.1 SELEX
    9.2 Others
10. Nucleic Acid Aptamers Market – by Application
    10.1 Therapeutics Development
    10.2 Drug Delivery Agent
    10.3 Analytical Reagent
    10.4 Food Inspection and Hazard Detection
    10.5 Diagnostics and Bio-Imaging Agents
    10.6 Others
11. Nucleic Acid Aptamers Market - by Geography
    11.1 North America
        11.1.1 the U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 the UK
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Chile
        11.4.4 Colombia
        11.4.5 Rest of South America
    11.5 Rest of the World
        11.5.1 the Middle East
        11.5.2 Africa
12. Nucleic Acid Aptamers Market - Entropy
13. Nucleic Acid Aptamers Market – Industry/Segment Competition Landscape Premium 
    13.1 Market Share Analysis
        13.1.1 Market Share by Region – Key companies
        13.1.2 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Nucleic Acid Aptamers Market – Key Company List by Country Premium Premium
15. Nucleic Acid Aptamers Market - Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
* "Financials would be provided to private companies on a best-effort basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.